Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Receptor interactions and binding mode of in hGPR
2022-04-13

Receptor interactions and binding mode of in hGPR40 were determined by docking studies. The compound was docked in the rebuilt co-crystal structure of hGPR40 (PDB ID: ) using MOE for loop modeling and energy minimization and Glide for molecular docking. The docking site used for the docking simulati
-
br FREE FATTY ACID RECEPTOR
2022-04-13

FREE FATTY ACID RECEPTOR 1 (GPR40) G-PROTEIN-COUPLED RECEPTOR 120 CONCLUSION Free fatty secreted frizzled related protein receptors whose natural ligands are identified as FFAs having various lengths have been reported. They act as novel nutrient sensing receptors independent of PPARs and
-
The results show that pimarane
2022-04-13

The results show that -pimarane and -strobane diterpenoids exert inhibitory effects on FXa suggesting that they may have potential as FXa inhibitor. However, it should be noted that some compounds such as compounds , , , and are poorly bioavailable. Thus, the current study indicates that the number,
-
Despite the two models for the HIV IN aptamer complexes
2022-04-13

Despite the two models for the HIV-1 IN-aptamer complexes appeared to be comparable, disintegration assays revealed that 93-del inhibited C– or N-terminally truncated enzyme at the same extent, [18] whereas, T30695 required N-terminal domain (NTD) of the enzyme to exert its integrase inhibitory acti
-
br ABT aR aR methyl hexahydropyrrolo b pyrrol yl
2022-04-13

ABT-288 (2-[4'-((3aR,6aR)-5-methyl-hexahydropyrrolo[3,4-b]pyrrol-1-yl)-biphenyl-4-yl]2H-pyridazine-3-one) is a selective H3R antagonist/inverse agonist developed by Abbott. Structurally, it is a compound with molecular weight (MW) 372.46 g/mol, three H-bond acceptors (HBA), and Moriguchi LogP (MLo
-
In fact most PIs are susceptible to substitutions
2022-04-13

In fact, most PIs are susceptible to substitutions at Asp168, which are often present in patients who fail therapy (Pawlotsky, 2016). Notably, the polymorphism Gln168 at this position underlies reduced efficacy of PIs against GT3 (Soumana et al., 2016a). Glecaprevir and voxilaprevir have improved re
-
Membrane based integrative treatment processes emerge as
2022-04-13

Membrane based integrative treatment processes emerge as potential solution compared to the conventional techniques. Gisi et al. (2009) presented a treatment scheme for tannery wastewater consisting of a biological pre-treatment and then a polymer as coagulant followed by reverse WY-14643 with a pla
-
Despite efforts over the past decade to shed
2022-04-12

Despite efforts over the past decade to shed light on the endosomal maturation process and its underlying Rab conversion, the context in which all the involved protein components interact needs to be further elucidated. After defining single components and modules of the machinery important for endo
-
PBI is an agonist of GPR and acts
2022-04-12

PBI-4050 is an agonist of GPR40 and acts as an antagonist or inverse agonist of GPR84. It cannot be excluded that other targets besides GPR40 and GPR84 could be implicated in the mechanism of action of PBI-4050 and could be explored in future studies. However, the present study, and in particular th
-
Recently an increasing number of studies have highlighted th
2022-04-12

Recently, an increasing number of studies have highlighted the crucial role of nociceptive factors produced by microglia under neuropathic pain conditions (Mika et al., 2013; Popiolek-Barczyk and Mika, 2016). iNOS is an important pronociceptive factor that is strictly expressed by microglia/macropha
-
Results from the current study
2022-04-12

Results from the current study are not consistent with those of a previous study (Poock et al., 2015) where there was no differences in ovulation induction response when there was administration of gonadorelin hydrochloride and gonadorelin diacetate salts. These differences in results are likely due
-
The fact that KNDy neurons activity is
2022-04-12

The fact that KNDy neurons activity is sensitive for circulating hormones related with control of Paxilline homeostasis was demonstrated in other studies (Cejudo Roman et al., 2012; Navarro et al., 2011). It is well documented that leptin plays an important role in the regulation of the gonadotroph
-
Obestatin increased GnRH mRNA expression in the POA
2022-04-12

Obestatin increased GnRH mRNA expression in the POA, being the main place of GnRH synthesis (Goodman, 2015). Simultaneously, obestatin also caused a decrease in the GnRH mRNA expression in ME, without affecting the level of this peptide mRNA in AHA. A lack of differences observed in the mRNA level i
-
br Expression of GlyT in the spinal
2022-04-12

Expression of GlyT in the spinal cord in response to neuropathic pain Twelve days after sham injury or CCI, GlyT1 and GlyT2 mRNA expression in rat spinal cord was analyzed using qPCR. Here, no significant changes in expression of the transporters in our CCI model of neuropathic pain compared with
-
Firefly Luciferase mRNA mg An alternative to the chemoenzyma
2022-04-12

An alternative to the chemoenzymatic preparation of glycoproteins is the production through total chemical synthesis or semi-synthesis [2,3,]. Many successful glycoprotein syntheses are based on native chemical ligation (NCL) [11], a reaction where unprotected peptides and glycopeptides of any lengt
16057 records 487/1071 page Previous Next First page 上5页 486487488489490 下5页 Last page